Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Shah

Showing results (51-60 of 3,190) with videos related to

Pageof 319
Sort By:
Drug Safety|August 19, 2016
Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic DilemmasRashmi R Shah
The Journal of Urology|March 29, 2000
Re: Pelvic fracture urethral injuries: the unresolved controversyS R Shah
Drug Safety|February 6, 2004
Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribingRashmi R Shah
Lancet (London, England)|November 13, 1982
Symptomatic bradycardia in association with H2-receptor antagonistsR R Shah
Healthcare Quarterly (Toronto, Ont.)|February 4, 2014
Diabetes in visible minority populations in OntarioBaiju R Shah
British Journal of Clinical Pharmacology|August 14, 2012
Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter?Rashmi R Shah
The Indian Journal of Chest Diseases|July 1, 1972
Diffuse interstitial pulmonary fibrosis: course and prognosisJ R Shah
Missouri Medicine|May 4, 2004
Genetic susceptibility to breast and ovarian cancer: risk assessment, genetic counseling, and management issuesMaulik R Shah
Drug Safety|February 5, 2005
Drugs, QT interval prolongation and ICH E14: the need to get it rightRashmi R Shah
The American Journal of Bioethics : AJOB|June 15, 2012
Increasing cesarean rates: the balance of technology, autonomy, and beneficenceKavita R Shah
Pageof 319

Showing results (51-60 of 3,190) with videos related to

Sort By:
Pageof 319
Drug Safety|August 19, 2016
Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic DilemmasRashmi R Shah
The Journal of Urology|March 29, 2000
Re: Pelvic fracture urethral injuries: the unresolved controversyS R Shah
Drug Safety|February 6, 2004
Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribingRashmi R Shah
Lancet (London, England)|November 13, 1982
Symptomatic bradycardia in association with H2-receptor antagonistsR R Shah
Healthcare Quarterly (Toronto, Ont.)|February 4, 2014
Diabetes in visible minority populations in OntarioBaiju R Shah
British Journal of Clinical Pharmacology|August 14, 2012
Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter?Rashmi R Shah
The Indian Journal of Chest Diseases|July 1, 1972
Diffuse interstitial pulmonary fibrosis: course and prognosisJ R Shah
Missouri Medicine|May 4, 2004
Genetic susceptibility to breast and ovarian cancer: risk assessment, genetic counseling, and management issuesMaulik R Shah
Drug Safety|February 5, 2005
Drugs, QT interval prolongation and ICH E14: the need to get it rightRashmi R Shah
The American Journal of Bioethics : AJOB|June 15, 2012
Increasing cesarean rates: the balance of technology, autonomy, and beneficenceKavita R Shah
Pageof 319